Regeneron price target lowered to $801 from $818 at Truist

Truist lowered the firm’s price target on Regeneron (REGN) to $801 from $818 and keeps a Buy rating on the shares. 2026 is critical for Eylea at this stage of the franchise’s tenure, with potential PFS – as a pre-filled syringe – Q2 approval and additional biosimilars entering later this year as key areas of focus, the analyst tells investors in a research note. Truist adds that its payer and volatility analyses suggest the Street may be underappreciating biosimilar entry impact to Eylea/Eylea HD share however.